Straits Times Index
3,204.82 +2.01 (+0.06%) Nikkei
32,402.41 -168.62 (-0.52%) Hang Seng
18,057.45 +402.04 (+2.28%) FTSE 100
7,683.91 +5.29 (+0.07%) Bitcoin USD
26,585.88 -37.32 (-0.14%) CMC Crypto 200
566.84 -1.20 (-0.21%)
Almirall, S.A. (0O9B.L)
| Previous close | 10.48 |
| Open | 10.43 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 10.36 - 10.57 |
| 52-week range | 10.36 - 10.57 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 18.143M |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.28 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Investing.com
Almirall's Ebglyss poised for EU approval, challenging Sanofi and Regeneron’s Dupixent
Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).
Business WireEBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
BARCELONA, Spain, September 15, 2023--Almirall S.A. (BME: ALM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the marketing authorization of EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy.
Business WireAlmirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business
BARCELONA, Spain, July 24, 2023--Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results.
